Strategic IP platform CHS Pharma holds an IP portfolio acquired from Florida Atlantic University and Hospital for Special Surgery with 4 issued patents, 2 allowed, and 8 applications pending, focused on asset candidates for Actinic Keratosis, Dry Macular Degeneration, Myocardial Infarction, and Ischemic Stroke. This positions the company for licensing or partnerships once candidates reach Phase II, highlighting opportunities to offer co-development, out-licensing deals, or milestone-rich collaborations.

Phase II potential Corporate strategy targets advancing drug candidates to Phase II before seeking strategic partnerships or licenses, signaling a clear inflection point for BD outreach around late-stage preclinical to early clinical development services, regulatory consulting, and CRO/PMO collaborations to de-risk and accelerate timelines.

Niche therapeutic focus Portfolio targets serious conditions with high unmet need including actinic keratosis-related cancers, dry macular degeneration, myocardial infarction, and ischemic stroke, suggesting sales conversations around targeted dermatology, neurovascular, and cardiovascular programs, as well as potential for companion diagnostics or personalized medicine partnerships.

Limited internal capacity Reported small team size (2-10 employees) implies reliance on external partners for R&D, clinical trials, regulatory affairs, and manufacturing, creating opportunities for CRO, CDMO, and subcontracting firms to offer scalable support and integrated development solutions.

Financial signal Revenue range of one to ten million dollars indicates a modestly sized biotech operation with budget leverage for strategic collaborations, licensing negotiations, and funded pilots with larger pharma or specialty biotech players seeking early-stage assets and risk-sharing arrangements.